Lorenzo Corsini

Managing Director, BioNTech R&D Austria

Lorenzo co-founded PhagoMed Biopharma, a biotech company focused on developing targeted antimicrobials based on synthetic endolysins, to treat antibiotic-resistant, biofilm- or microbiome -related conditions. He led PhagoMed as CEO until it was acquired by BioNTech in 2021 and renamed into BioNTech R&D (Austria), which Lorenzo now leads as Managing Director. Prior to starting PhagoMed in 2017, he was a Principal at the Boston Consulting Group. He did his PhD in molecular biology at EMBL Heidelberg and has diploma degrees in biochemistry and business administration.